Author Archives for Adeline Chauvigné

Green light for the european BOOST4HEALTH project

On February the 25th, the European project Boost4Health successfully passed the final selection step at the North West Europe INTERREG... View Article

Murielle Cazaubiel elevated to the rank of Knight of the Legion of Honor

On March 7th, in the presence of the Prefect, Murielle Cazaubiel, manager of Biofortis Merieux Nutrisciences, received the insignia of... View Article

Join the Bioregate Forum 2016 in Nantes!

Bioregate Forum is a biannual European meeting dedicated to highlighting latest scientific, technological, clinical & commercialization approaches in the field... View Article

Effimune & Ose Pharma announce proposed merger to create significan immunotherapy player

OSE Pharma, an immuno-oncology company with a specific immunotherapy activating T lymphocytes, currently in a registration Phase 3 study, and Effimune, a... View Article

Rédigé par Adeline Chauvigné, le 2016-03-21

Effimune & Ose Pharma announce proposed merger to create significan immunotherapy player

OSE Pharma, an immuno-oncology company with a specific immunotherapy activating T lymphocytes, currently in a registration Phase 3 study, and Effimune, a... View Article

Valneva Announces $42 Million IXIARO® Supply Contract with US Government

Valneva SE (“Valneva” or “the Company”), a leading pure play vaccine company, announces today the signing of a $42 million... View Article

Rédigé par Adeline Chauvigné, le 2016-03-21

Valneva Announces $42 Million IXIARO® Supply Contract with US Government

Valneva SE (“Valneva” or “the Company”), a leading pure play vaccine company, announces today the signing of a $42 million... View Article

Effimune and In Cell Art collaborate to develop a novel therapeutic approach in immunology

PR 110216Final The two biotechnology companies in Nantes develop a novel approach aiming at the production of therapeutic antibodies directly... View Article

Rédigé par Adeline Chauvigné, le 2016-02-11

Effimune and In Cell Art collaborate to develop a novel therapeutic approach in immunology

PR 110216Final The two biotechnology companies in Nantes develop a novel approach aiming at the production of therapeutic antibodies directly... View Article

Atlanpole Biotherapies joins CEBR Board

The Council of European BioRegions (CEBR) is a network of biotechnology support professionals that support their local biocommunity through direct services including... View Article

Porsolt expands with the acquisition of Fluofarma

Porsolt has acquired Fluofarma, a Bordeaux-based company focused on the provision of cell-based assays and in vitro screening services. The... View Article

Rédigé par Adeline Chauvigné, le 2016-02-11

Porsolt expands with the acquisition of Fluofarma

Porsolt has acquired Fluofarma, a Bordeaux-based company focused on the provision of cell-based assays and in vitro screening services. The... View Article

IFB-088 (Sephin1) receives orphan drug designation in the European Union for the treatment of Charcot-Marie-Tooth disease

InFlectis BioScience announces that the European Commission has granted orphan drug designation to its drug candidate IFB-088, also known as... View Article

Rédigé par Adeline Chauvigné, le 2016-02-11

IFB-088 (Sephin1) receives orphan drug designation in the European Union for the treatment of Charcot-Marie-Tooth disease

InFlectis BioScience announces that the European Commission has granted orphan drug designation to its drug candidate IFB-088, also known as... View Article

CESTI IHU: Predicting transplant rejection to better anticipate it

The objectives of the programs led by Dr. Sophie Brouard and Pr. Antoine Magnan within the CESTI IHU are to... View Article

Rédigé par Adeline Chauvigné, le 2016-02-11

CESTI IHU: Predicting transplant rejection to better anticipate it

The objectives of the programs led by Dr. Sophie Brouard and Pr. Antoine Magnan within the CESTI IHU are to... View Article